Breaking News, Financial News

Financial Report: Hospira

Specialty Injectable sales up 12% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hospira 4Q Revenues: $1.1 billion (+8%) 4Q Earnings: $5.3 million (loss of $214 million 4Q11) FY Revenues: $4.1 billion (+1%) FY Earnings: $44.2 million (loss of $9.4 million FY11) Comments: Growth in the quarter was driven strong sales of Specialty Injectable Pharmaceutical (SIP) products, up 12% to $696 million, including Precedex globally and oncolytic oxaliplatin in the U.S., as well as higher volumes for certain products in the EMEA region. SIP sales in the Americas were  $539.6 millio...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters